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Abstract
Objective. To explore barriers and facilitators to implementing an evidence-based clinical decision support (CDS)
tool (BREASTChoice) about post-mastectomy breast reconstruction into routine care. Materials and Methods. A
stakeholder advisory group of cancer survivors, clinicians who discuss and/or perform breast reconstruction in
women with cancer, and informatics professionals helped design and review the interview guide. Based on the
Consolidated Framework for Implementation Research (CFIR), we conducted qualitative semistructured interviews
with key stakeholders (patients, clinicians, informatics professionals) to explore intervention, setting characteristics,
and process-level variables that can impact implementation. Interviews were transcribed, coded, and analyzed based
on the CFIR framework using both inductive and deductive methods. Results. Fifty-seven potential participants
were contacted; 49 (85.9%) were eligible, and 35 (71.4%) were enrolled, continuing until thematic saturation was
reached. Participants consisted of 13 patients, 13 clinicians, and 9 informatics professionals. Stakeholders thought
that BREASTChoice was useful and provided patients with an evidence-based source of information about postmastectomy breast reconstruction, including their personalized risks. They felt that BREASTChoice could support
shared decision making, improve workflow, and possibly save consultation time, but were uncertain about the best
time to deliver BREASTChoice to patients. Some worried about cost, data availability, and security of integrating
the tool into an electronic health record. Most acknowledged the importance of showing clinical utility to gain institutional buy-in and encourage routine adoption. Discussion and Conclusion. Stakeholders felt that BREASTChoice
could support shared decision making, improve workflow, and reduce consultation time. Addressing key questions
such as cost, data integration, and timing of delivering BREASTChoice could build institutional buy-in for CDS
implementation. Results can guide future CDS implementation studies.
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breast cancer, breast reconstruction, clinical decision tool (CDS), decision aids, shared decision making
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Introduction
Clinical decision support (CDS) tools help patients
and clinicians make better decisions about clinical
care through a centralized platform.1 CDS tools have
the potential to enhance patient care delivered from
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clinicians and other medical staff. These tools can
improve knowledge, provide an algorithm or strategy for
choices, and sometimes offer an individualized risk prediction model based on the patients’ health history.1
When used to support shared decision making, CDS
tools can provide information to patients, help them
clarify their preferences, and prepare them for decisions
and possible outcomes.1
Despite their utility, CDS tools are often not incorporated into routine care. Documented barriers to adopting
CDS tools in practice include limited consultation time,
resource constraints, complexity surrounding technological implementation, and institutional challenges for sustaining the use of these tools over time.2 In addition to
demonstrating clinical utility, implementing CDS tools
into routine care requires engaging stakeholders, understanding their preferences, and addressing potential barriers to their routine adoption.2 A treatment decision
that would benefit greatly from decision support is the
choice about breast reconstruction after mastectomy.
About 40% of patients choosing a mastectomy opt to
undergo post-mastectomy breast reconstruction to
restore breast shape when a natural breast is removed.3
Although it is a preference-sensitive decision with no single best option for all patients, and should be guided by
both clinical evidence and patient preferences, not all
patients and clinicians engage in shared decision making
about post-mastectomy breast reconstruction.4,5 In fact,
many patients report feeling ill-prepared for the potential
risk of complications after immediate breast reconstruction, and many clinicians underestimate the patients’
risks.6 In the broader population, there is about a 25%
risk of complications associated with immediate breast
reconstruction, but this risk varies widely and is affected
by patient characteristics.4,7 Immediate breast reconstruction after mastectomy has a higher rate of complications and higher risk of flap or tissue expander/implant
failure, compared to delayed reconstruction.8,9 However,
Division of Public Health Sciences, Department of Surgery (JB, KS,
CG, MCP); Division of General Medical Sciences (REF); Division of
Plastic and Reconstructive Surgery, Department of Surgery (TMM),
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Department of Plastic Surgery, Ohio State University, Wexner Medical
Center, Columbus, Ohio (CNL). The author(s) declared no potential
conflicts of interest with respect to the research, authorship, and/or
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more women opt for immediate breast reconstruction
compared to delayed reconstruction because it can
improve aesthetic results and reduce the amount of time
a woman is without a breast shape.9,10
In a past project, we developed a CDS tool called the
Breast Reconstruction Education and Support Tool
(BREASTChoice), a web-based decision aid for women
with breast cancer considering post-mastectomy breast
reconstruction.6 To address the variable and often high
risk of complications, knowledge gaps, and support
women’s decision about options, BREASTChoice incorporates plain language about breast reconstruction,
allows women to consider their preferences for reconstruction options, and provides a personalized prediction
for risk of complications from immediate breast reconstruction.6 Findings from the earlier randomized trial
showed that it improved patients’ knowledge and decision confidence without affecting consultation time.
However, clinicians were often not aware of which
patients used the CDS tool. Electronic health record
(EHR) integration with a summary of risk and preferences could help clinicians and patients engage together
in shared decision making rather than focusing mostly
on activating patients.6
We refined BREASTChoice such that the risk prediction model—built and validated in over 17,000 people9
and updated with institutional data—would be autopopulated with data from the patient’s EHR, and the
summary of her risk and preferences would be sent back
to the EHR for use at the point of care.6,11 The purpose
of this article is to describe stakeholder perceptions of
implementing the refined BREASTChoice tool into the
EHR and ultimately into routine care. For this study, the
women interviewed were past the decision-making process and reflecting on their experiences. We report on a
series of qualitative semistructured interviews conducted
based on a well-established framework, the Consolidated
Framework for Implementation Research (CFIR).12

Methods
Conceptual Framework
Interview guides were developed for participants
(patients, clinicians, and informatics professionals) using
CFIR constructs. The CFIR framework guided interview questions about ways to adapt and refine
BREASTChoice and was used to develop the codebook
for analyzing interview transcripts. A stakeholder advisory group (SAG) and the study team reviewed and
modified the guide for clarity and relevance to the
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research questions. The CFIR constructs comprise five
main domains:
1.

2.

3.

4.

5.

Intervention Characteristics: Stakeholder perceptions
about the intervention (e.g., adaptability and relative
advantage over other existing interventions)
Outer Setting: The extent to which outside influence
such as external policy at other organizations may
impact decisions considered during the implementation process (e.g., patient needs and resources)
Inner Setting: Attributes of the organization that
might affect the implementation process (e.g., implementation climate)
Characteristics of Individuals: Attributes of individuals involved with the intervention and how that will
affect the implementation process (e.g., other personal attributes, knowledge and beliefs, and intervention complexity)
Process: Methods that impact the implementation
process of the intervention (e.g., engaging local
champions)

eligible participants were contacted by phone or email to
determine eligibility and interest
Eligible patients were 18 years or older, Englishspeaking, who had a mastectomy for malignancy within
the last 5 years, and completed surgical therapy. We
aimed to recruit women who previously had stage 0 to 3,
non-metastatic breast cancer (since those with metastatic
disease face different surgery decisions). Eligible clinicians were included if their primary practice area was
counseling or caring for patients with breast cancer who
were considering breast reconstruction. Clinicians were
recruited from three institutions (including two academic
and one community health center) and one national
foundation. Clinicians included plastic and reconstructive surgeons, surgical oncologists, medical oncologists,
radiation oncologists, and primary care clinicians.
Interest and experience with shared decision making was
not a criterion for eligibility. Eligible informatics professionals included individuals with expertise in integrating
CDS tools into EHRs. Informatics experts were all
affiliated with one of two academic institutions who used
the same EHR system; however, the informatics experts
also had knowledge about other EHR systems.

Study Team
We engaged a SAG of cancer survivors, clinicians who
discuss and/or perform breast reconstruction in women
with cancer, and informatics professionals from academic and community sites. The SAG complemented the
scientific research team, which included plastic and
reconstructive surgeons, epidemiologists, informatics
experts, decision scientists, biostatisticians, and research
coordinators.

Recruitment and Eligibility
Prior to recruitment, approval for the study was obtained
from the Institutional Review Board (IRB: reference #
201908112) at Washington University’s school of
Medicine from the Human Research Protection Office
(HRPO). We engaged stakeholders from multiple geographic areas and practice sites, using purposive and
snowball sampling with the aim that at least 50% of our
patient interviews would be with Black and/or elderly
women over age 65. We partnered with the SAG and
community and national organizations, including the
Breakfast Club, Inc.; Living Beyond Breast Cancer; and
the Plastic Surgery Foundation, to identify a range of
participants to approach for interviews. We also leveraged local and regional connections to identify patients,
clinicians, and informatics professionals. Potentially

Interview Procedures
Participants were sent a .pdf containing screenshots of
the BREASTChoice tool prior to the interview, and a
link to BREASTChoice housed on a website outside the
EHR to navigate through the pages. On the day of the
interview, the purpose of the study was explained, and
participants completed informed consent. Interviews
were conducted by a masters-level research coordinator
either in-person or over the telephone between December
2019 and May 2020. She was trained and supervised by
the principal investigators (PIs) of the study, who both
have experience with qualitative interviewing and analysis. Interview questions were designed to assess CFIR
constructs such as stakeholders’ views on implementation barriers and facilitators, perceptions of the tool,
views on relative advantages of implementation, difficulty of implementation, time of implementation, and
external policies and incentives as they pertained to the
BREASTChoice tool (see Supplementary Appendix A
for the interview guide). Interviews were audio recorded,
conducted at the workplace or by phone, and lasted
about 20 to 40 minutes. Field notes were taken during
each session. After the interview, participants completed
a brief survey to assess demographic and professional
characteristics. Participants received a $20 gift card as an
incentive.
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Data Analysis
Methods and results are reported in accordance with the
Consolidated Criteria for Reporting Qualitative Studies
(COREQ).13 Recordings were transcribed using a professional transcription service and de-identified. Transcripts
were coded using QSR NVivo 12 using a codebook
developed by research team members (CG, JB, MP, CL)
based on the CFIR framework. Two team members (JB
and KS) supervised by the principal investigator (MP)
double-coded seven transcripts and checked for interrater
reliability (kappa .0.8 and percent agreement .95%).
They discussed discrepancies, revised the codebook as
needed, and double-coded six more transcripts. Once
interrater reliability was obtained a second time, the
remaining transcripts were coded independently.

Funding Source
Financial support for this study was provided by a grant
from the Agency for Healthcare Research and Quality
(AHRQ; R18 HS026699). The funding agency had no
role in designing the study, interpreting the data, writing,
or publishing the report.

Results
Fifty-seven potential participants were contacted; 49
(85.9%) were eligible, and 35 (71.4%) were enrolled.
Eight were ineligible, and 14 did not respond to requests
to schedule interviews or were not interested. The final
sample included 13 patients, 13 clinicians, and 9 informatics professionals. The team discussed findings after
three to five interviews and continued this process until
thematic saturation was achieved. For example, we interviewed more informatics experts when we learned we
had not reached saturation in this stakeholder group.
We reached data saturation because we were focusing on
EHR integration, rather than the tool content itself or
on patients’ experiences with breast reconstruction.
Table 1 displays participant characteristics. Below, we
describe themes that emerged from the data within specified CFIR constructs, with illustrative quotes.

Theme 1: When asked about the advantages of
the tool, stakeholders found the tool useful and
thorough overall [CFIR constructs: Relative
Advantage, Knowledge and Beliefs]
Theme 1.1: Clinicians, informatics professionals, and
patients agreed that BREASTChoice provided a source

MDM Policy & Practice 6(2)

Table 1 Participant Characteristics (N = 35)
Characteristics

Number (%)
unless indicated

Patient
N = 13 (100)
Age
Mean (SD, range)
51.8 (12.2, 41–71)
Gender
Female
13 (100)
Racial group
White
9 (69.2)
Black/African American
2 (15.4)
Another race
2 (15.4)
Current health insurance
Private
10 (76.9)
Government (Medicare and Medicaid)
3 (23.1)
Household income
Less than 30,000
2 (15.4)
30,000 to 60,000
2 (15.4)
More than 60,000
7 (53.8)
Prefer not to answer
2 (15.4)
Breast cancer stage
Stage I
2 (15.4)
Stage II
4 (30.8)
Stage III
5 (38.5)
Don’t know
2 (15.4)
Type of reconstructive surgery
Implant
9 (69.2)
Flap or tissue-based
3 (23.1)
No reconstruction
1 (7.7)
When did you start reconstruction
Immediately
9 (69.2)
Delayed
3 (23.1)
N/A
1 (7.7)
Clinician
N = 13 (100)
Gender
Male
4 (30.8)
Female
9 (69.2)
Racial group
White
9 (69.2)
Asian American
3 (23.1)
Another race
1 (7.7)
Clinician background
MD
9 (69.2)
PA/physician assistant
2 (15.4)
NP/nurse practitioner
1 (7.7)
RN/registered nurse
1 (7.7)
Years in practice (range)
Less than 10
7 (53.8)
10–20
3 (23.1)
21 or more
3 (23.1)
Geographic area of practice
Urban
8 (61.5)
Suburban
3 (23.1)
2 or more
2 (15.4)
Informatics professionals
N = 9 (100)
Gender
Male
3 (33.3)
Female
6 (66.7)
(continued)
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Table 1 (continued)

Characteristics

Number (%)
unless indicated

Racial group
White
5 (55.6)
Black/African American
1 (11.1)
Asian American
3 (33.3)
Type of work
Healthcare informatics
6 (66.7)
Hospital administration
1 (11.1)
Both
2 (22.2)
Years in informatics or hospital administration (range)
Missing
1 (11.1)
Less than 10
3 (33.3)
11–15
3 (33.3)
16–20
2 (22.2)
Experience with CDS tools
Yes
6 (66.7)
No
3 (33.3)

individualized and critical topics of discussion with them
rather than kind of going over some of the basic aspects of
reconstructive surgery. (Clinician #121)
From a physician’s standpoint, it would help me get a better
understanding of the patient’s concern because the report
has put them in a good format. And then I could go over
those concerns and help with the patient and come up with
a plan that works for all parties. (Clinician #132)
I like . . . that [the] conversation can be started where the
clinician and the patient are jointly making the decisions
together and going through that . . . decision process
together. (Patient #150)
Some women . . . may feel like they’re being rushed into
making a decision, but with this tool, they can kind of sit
back and say, ‘‘Okay, here are my options. I thoroughly
understand what’s in front of me. Now it’s up to me to make
a decision that’s best for me.’’ (Patient #159)

CDS, clinical decision support.

Theme 1.3: Stakeholders thought that personalized risk
information can help clinicians explain to patients why certain options might not be the right fit.
of centralized, evidence-based information about reconstruction.
It gives the patient a realistic outline of pros and cons of
what their selected choices are, and . . . takes away the overwhelming information that they may seek if they were
Googling this information. It’s just giving a very straightforward, ‘‘This is your pro. This is your con.’’ (Clinician #129)
It was good at gathering and pulling my thoughts together
in one place. That is definitely something that is going to
help . . . most women . . . especially right at the time when
they get their diagnosis and they’re trying to decide what
they’re going to do . . . their brain is all over the place.
(Patient #150)
You get more information [from BREASTChoice]. . . . I
remember when I was making my decisions. I just talked to
my surgeon and my plastic surgeon, in hindsight, I didn’t
have maybe a full picture of all of my range of choices . . . it
would’ve been nicer to have—to have had a little bit more
information to—to make those decisions. (Patient #152)

Theme 1.2: Clinicians and patients felt that
BREASTChoice could support shared decision making,
improve workflow, and save consultation time.
It would not only help patients make the decisions but also,
you know, improve efficiency. . . . Given the limited time we
have with each patient, it allows us to then focus on . . .

It would only enhance the conversation—because I think
patients who are higher risk—those who have been radiated,
have high BMIs [body mass indices], have multiple comorbidities, it’s good for them to know at the beginning that
the doctor may recommend not doing immediate reconstruction, may recommend that you wait so you can quit
smoking before you do this elective operation . . . something
like that. (Clinician #134)
[The personalized risk] would be good because then they
can explain further why these are higher risk . . . they’ll be
there to reiterate . . . the risk factors. (Clinician #131)
If you put all that in and it comes back and says, your risk
of complications is 95%. That makes me say, it’s not worth
it. I mean maybe I shouldn’t look at that avenue, or I should
just do this type of reconstruction or no reconstruction,
because it could be a useful tool for some people who are on
the fence. (Patient #155)

Theme 1.4: Clinicians and patients particularly liked the
realistic and diverse photos of reconstruction outcomes.
Having the pictures were very helpful for patients, too, so
that they can get an idea of realistically what to expect after
breast reconstruction or no reconstruction. (Clinician #127)
There were some really good outcomes of the surgeries and
then there were some that weren’t as great . . . people could
get kind of a picture of both. (Patient #150)
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It was really good to see [from the pictures], oh, that’s [my
result] not that bad. . . . I got used to the image, so it’s not a
problem. But when you see yourself at the mirror, the first
time, even if you think you ready, you’re not, so I think—
the image [photos] is really good. (Patient #162)

Theme 2: When asked specifically about the
content, color, graphics, and aesthetics of the
tool, some stakeholders suggested content or
formatting edits [CFIR constructs: Design
Quality Packaging and Compatibility]
Theme 2.1: Clinicians and informatics experts thought
having more graphics will help women understand the
information better.
It’s important that women see what it looks like in clothes
also. (Clinician #132)
Using some more graphs or figures to summarize would be
much easier for patients. (Informatics #102)

Theme 2.2: The tool felt long at first to some stakeholders,
but no one had suggestions for parts to remove, and in fact,
many had suggestions for additions to consider. Most
patients indicated that the tool was the right length.
Because it’s so sophisticated and thorough, it’s very long,
for people to go through . . . if they go through it, they’re
going to find it very helpful. I just think that they’re going
to have to be prepared. . . . They’re going to have to know
that this is . . . a lot of information. (Clinician #130)
It was a little bit lengthy, but there’s a lot of considerations,
when you’re making that decision. So, I don’t know how
you would shorten it. (Patient #152)
You know, at first when I was looking at it, I said, ‘‘Oh, my
God, this is long.’’ But then as I got into it, it didn’t really
feel like it was because it was providing me with information
that I needed. (Patient #159)

Theme 3: When asked about possible challenges
with integrating the tool within the EHR, some
worried about the cost, timing, and security of
integration, and suggested ways to simplify the
programming [CFIR constructs: Adaptability,
Cost, Complexity, and Intervention Source]

Theme 3.1: Informatics professionals worried about the
expenses associated with developing and implementing
BREASTChoice into the EHR.
It comes at a cost because you have to be able to maintain it
. . . and sometimes that can be difficult to do . . . as staff
changes, the level of knowledge changes and the ability to
do that—familiarity with how it works. (Informatics #109)
It’s going to cost you a lot of money to build this. That’s just
the reality. (Informatics #101)

Theme 3.2: Informatics professionals and patients
expressed concern about the security of protected health
information (PHI) and cautioned about the length of time
to get the process approved.
You’ll need to make sure that you . . . discuss this with some
of our legal representatives . . . you want to make sure that
that data governance is very clear of who owns data and
where it’s stored and so that it’s not, there’s no PHI that’s
being shared. (Informatics #107)
We’re really conservative from an information-security
standpoint, so if it’s not really in [the EHR] but it’s essentially an outside tool, then how is it going to get information
out? . . . those things are not trivial . . . you’d have to get all
the right authorizations . . . going to link out of [the patient
portal], and then you’re pulling information back in, so just
the general technical and privacy related to that.
(Informatics #108)
I’m definitely curious about how safe it is. Like how is it
being managed? You know, what’s the chance of maybe
being leaked to, third party companies or other for-profit
people who just wanted my data for their money? (Patient
#153)
So, the issue here is there is a [patient portal name] build.
There’s an [EHR] integration. There’s an [EHR] calculator
. . . there’s multiple pieces here. This is a big build.
(Informatics #101)

Theme 3.3: Patients felt comfortable with the EHR auto
populating the risk model with their health information, if
that information would be safeguarded. It was important
that patients could modify their health risk information in
case some data were inaccurate or missing.
As long as it’s like a password-protected login situation, I’d
probably be happy that they [health care team] had my
information and knew who I was and my specifics. (Patient
#151)

Boateng et al.

As long as it’s all within the same medical channels, I don’t
have any problem with that. . . . I think it’s good to have
that information shared as long as it’s not sharing that
information with other private organizations that can use it
to maybe target me for ads or like marketing or whatever
that would be where I would not want things shared.
(Patient #156)
You might actually get better information if you just ask
patients directly [some of the risk questions] . . . all of the
questions are things that I think most patients would be able
to answer . . . with more reliability than pulling it from a
health record. . . . Although it’s cool to hook this up to the
EHR, it might actually be easier to just have them answer.
(Informatics #103)

Theme 4: When asked about the best timing to
deliver the tool, stakeholders differed in their
perspectives, but felt that patients needed some
time before or after a clinical encounter to process
a cancer diagnosis to think about reconstruction
[CFIR constructs: Implementation Climate and
Other Personal Attributes]
Theme 4.1: Clinicians and patients had different opinions
on when to deliver the tool.
[The timing of sending them the tool?] . . . that’s hard. I
guess whenever they meet with a plastic surgeon . . . they’re
going to be discussing reconstruction. . . . I guess it depends
on how soon they’re having surgery if they’re doing a mastectomy right away but aren’t ready to go through the reconstruction process. That’s a tough question. (Clinician #131)
Right after they’re diagnosed, they come and talk to the
breast surgeon. Most of the surgeons, then, either talk to
them again after that, or they’ll set them up for another
appointment. I think after that they need a little bit of time
to process what this diagnosis is. So, I think if you do it
[send out the link], say a week after their diagnosis—that
might be helpful. (Clinician #133)
At least for me, I was trying to plan and schedule everything,
and they’re like oh, three weeks for an appointment, you
know, four weeks for this if you have this, cool. In that time
while you’re waiting, you would feel somewhat productive,
and then you would have the information to take to the different doctors. (Patient #155)

Theme 4.2: Informatics professionals and patients emphasized making the tool accessible from multiple devices, to
maximize flexibility for patients.
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Making it as accessible as possible, so giving them an option
of how to do it, whether on the computer and a mobile
device, letting them do it at home or in the clinic, so having
some flexibility. (Informatics #107)
That’s another reason why a link from an email is good
because you can go there from your phone or from your laptop. Because . . . you’re sitting at chemo and your infusion,
but you’re on your phone. You’re probably not bringing
your laptop. And then, you’re home resting. Then, you’re
on your laptop because you don’t want to be holding your
phone. (Patient #151)

Theme 4.3: Clinicians and patients differed regarding
where patients should complete the tool.
The only hesitation that I have with them doing it in the
waiting room is that we generally have a mix of patients . . .
it may make the breast patient uncomfortable to, have pictures of different kind of breast reconstruction and then the
guy next to her is there for a broken hand, and he’s like,
‘‘Oh, what’s that?’’ (Clinician #129)
Making it as accessible as possible, so giving them an option
of how to do it, whether on the computer and a mobile
device or letting them do it at home or in the clinic, so having some flexibility with how patients are able to use it.
(Informatics #107)
I would think [patients should complete it] at home. You
know, when you’re in the waiting room, there’s distractions
when—and you don’t know how long you’re going to wait,
so you might get halfway through the tool, and they call you
back. I think—at home would—be the least distracting and
would enable you [the patient] to complete it all in one sitting. (Patient #152)

Theme 5: Stakeholders commented that
institutional support is important before
implementation; several clinicians and
informatics professionals mentioned individual
champions to contact about BREASTChoice
implementation [CFIR constructs:
Implementation Climate, Engaging, Champions]
Theme 5.1: Clinicians and informatics experts suggested
that we include key personnel within health institutions to
encourage potential uptake of the tool.
The other cancer plastic and reconstructive surgeons that I
work with would all very much support and embrace the
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concept and use of something like BREASTChoice.
(Clinician #121)
The first hurdle is finding the right stakeholder group [to
approve the CDS process]. Once you find the stakeholder
group, making sure that the request gets there and is represented . . . the stakeholder group is really the most important one, so make sure the project’s vetted and it’s, aligned
with our organizational goals [listed several informatics professionals to contact]. (Informatics #105)
When I say showing the benefit, I mean, showing that it
applies to both the patient and clinician who is seeing that
patient, too. Because the more accurate information and the
more people that use the tool the more likely it is that people are going to keep using it. As well as the more informed
the clinician’s going to be when they see that patient at that
visit. (Informatics #109)

Theme 5.2: Clinicians and informatics experts indicated it
might be difficult to implement a new tool that would alter
clinicians’ routines.
All of us have a very wide variable practice pattern even
though we are all fellowship-trained, surgical oncologists,
breast surgical oncologists. And, we also have varying
lengths of practice having been in practice and so I think
there’s going to be a ton of variation in usage. (Clinician
#126)
I think anything new that comes out, especially even with
clinicians sometimes they’re so used to their routine that
introducing new changes to them can be difficult to adopt
without you proving why it’s useful. So, I think, that the
marketing and adoption piece is probably the thing that I
would think would be the most difficult, even if us looking
at it and go like, ‘‘Huh. This is a great tool.’’ (Informatics
#109)

Discussion
This project explored stakeholder perceptions of implementing a CDS tool into routine care. Stakeholders felt
BREASTChoice could support shared decision making
if delivered at the right time during the care pathway.
Many stakeholders had no strong preference for where
to place the summary of risk and preferences in the EHR
but wanted guidance and a brief training to help them
identify the location and remember to look there prior to
an encounter. Informatics professionals cautioned about
the cost associated with building and maintaining the
tool and gave us insight into the importance of testing
the tool using an external link prior to integration into

the EHR. They also suggested ways to maintain the privacy of patients’ health information when integrating a
tool into the EHR. All stakeholders acknowledged the
importance of flexibility in accessing the tool from various devices and getting buy-in from key leaders at the
organization to support routine adoption. Several participants mentioned specific clinician and informatics
champions to engage. Overall, findings suggest that CDS
tools should be designed with extensive stakeholder
engagement and that usability testing can be built into
project timelines to address workflow and security concerns before implementation.
It is important to engage multiple stakeholder groups
to ensure that tools designed to work within health
care systems respond to the unique needs and goals of
each. Integration processes involve several approval
stages, interfacing with informatics teams and the appropriate governance groups at each study/implementation
site.14,15 Moving forward, the tool could be automated
and emailed to the participants who are eligible and give
consent. Clinicians did mention clinical nurse coordinators as possible people to send the tool to patients.
Results are consistent with past work exploring stakeholder perspectives about CDS.5 For example, in the
context of cardiovascular health, clinicians were satisfied
with CDS tools to support decisions, though they raised
concerns about how to incorporate the tool into routine
care due to workflow and time constraints16 that could
be addressed through usability testing and stakeholder
engagement. Similarly, a scoping review analysis on
CDS tools found an increased interest in communication
between clinicians and patients and an increase in clinician knowledge about patients’ health after using these
tools.11 CDS tools can improve patient-centered care
and enhance health outcomes17 when barriers to implementation are addressed. Several stakeholders commented on the importance of collaboration across multiple
professional backgrounds to design and implement a
CDS tool such as BREASTChoice.

Strengths and Limitations
This project engaged stakeholders from across geographic areas and practice sites, using principles of
designing for dissemination18 and the CFIR framework
to increase the likelihood that the CDS tool can be incorporated into routine care.12 This process provided input
on data integration and privacy concerns from each site.
Interview questions were open-ended and allowed participants to express their views in-depth. Limitations of
these interviews is that they were primarily conducted at
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sites familiar with implementing CDS in EHRs and thus
might not reflect the viewpoints of those who are less
experienced with the process. In addition, we did not
send a live, EHR-integrated tool during this step, because
we had planned to incorporate feedback from these stakeholders into the content, format, workflow process,
and EHR based components of the tool prior to EHR
integration. We did not include non-English-speaking
patients in this study or create a CDS tool in a language
other than English. Patients were also mostly insured and
might not represent the needs of the general population
of women considering post-mastectomy breast reconstruction. Additionally, patients contacted through the
community and national organizations might have more
knowledge about breast cancer compared to women who
are not. Few nurses and other support staff participated,
and they might counsel women about breast reconstruction, in addition to surgeons. Informatics experts were
from institutions that used the same EHR platform
(Epic) in their work, though they had experience with
others; other EHR systems may present unique barriers
to CDS implementation.

Conclusion
Developing and implementing CDS tools requires extensive stakeholder engagement to ensure clinical utility and
applicability. Usability testing and institutional support
can help address workflow and resource limitations that
might emerge during formative work. Future studies will
evaluate the implementation process for BREASTChoice,
assessing both clinical and implementation outcomes to
strengthen support for broader dissemination.
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